stockrowPersonalis, Inc.
PSNL Healthcare Diagnostics & Research
Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024.
- Revenue
- +76.6%
- EPS
- −33.3%
- Free cash flow
- −15.5%
Quarter to September 2026, against a year earlier
Follow PSNL
Alert me
Personalis, Inc. (PSNL) EV/Sales
As of 5 November 2026, Personalis, Inc. (PSNL) trades at a EV/Sales of 18.6×. Over the past ten years it has ranged from −1.3× (December 2022) to 25.0× (August 2026); the current reading is higher than 96% of that period. That is above the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.0× | 238.14% |
| FY2024 | 2.1× | 7,101.04% |
| FY2023 | 0.0× | — |
| FY2022 | −0.9× | — |
| FY2021 | 4.2× | (69.38%) |
| FY2020 | 13.6× | 934.06% |
| FY2019 | 1.3× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 19.5× | 11.37% |
| Jun 2026 | 17.5× | 151.49% |
| Mar 2026 | 7.0× | (0.87%) |
| Dec 2025 | 7.0× | 8.70% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FRNM Freenome, Inc compare | n/m |
| CSTL Castle Biosciences, Inc. compare | 2.1× |
| VCYT Veracyte, Inc. compare | 2.5× |
| OPK OPKO Health, Inc. compare | 2.8× |
| NEO NeoGenomics, Inc. compare | 3.3× |
| WGS GeneDx Holdings Corp. compare | 4.2× |
| CDNA CareDx, Inc. compare | 7.6× |
| ADPT Adaptive Biotechnologies Corporation compare | 14.6× |
| PSNL Personalis, Inc. | 18.6× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)